Skip to main content
. 2022 Feb 20;14(4):1071. doi: 10.3390/cancers14041071

Figure 5.

Figure 5

Lower levels of intratumoral MYL6 correlate with a poor outcome for melanoma patients. (A): Relative mRNA levels of MYL6 in SkMel28 cells 24, 48, 72 and 96 h after knockdown of ADCK2. MYL6 was significantly downregulated in SkMel28 cells treated with siADCK2 compared to the siControl group. Statistical analysis was conducted with paired t-test. n = 4. (B): Representative images of an immunofluorescence staining of SkMel28 cells 48 h after transfection with either siControl or siADCK2. The amount of MYL6 was greatly reduced after ADCK2 knockdown. Red = Actin; green = MYL6; blue = DAPI. (C) The analysis of data from two distinct melanoma datasets from the GEO database revealed a positive correlation between ADCK2 and MYL6 expression. Statistical analysis was performed with Pearson correlation. (D): Kaplan–Meier Curves from two distinct datasets from the cBioPortal and the GEO database (GSE_65904) showed that a higher level of intratumoral MYL6 goes along with better disease-specific survival of melanoma patients. Statistical analysis of the survival data was performed with a log-rank test. Median survival: left graph high = 31.27, low = 6517 months; right graph high = undefined, low = 28.3 months. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001.